Browsed by
Author: blogadmin

High levels of lean muscle may help prevent Alzheimer.

High levels of lean muscle may help prevent Alzheimer.

Comments 0 Comment

High quantities of lean muscle may help prevent Alzheimer’s disease, according to recent studies. To determine whether this connection is causal, more study is required.

Resistance training and a sufficient intake of protein in the diet are advised by experts as ways to build lean muscle mass. Previous studies have shown a link between obesity and an elevated risk of Alzheimer’s.

A recent study that was published in BMJ Medicine suggests that having a lot of lean muscle may prevent Alzheimer’s disease. The authors of the study pointed out that additional study is required to comprehend the biological mechanisms underlying it.

Researchers gathered data on 450,243 participants’ genetics, lean muscle mass, cognition, and health for this study from the U.K. Biobank. They next used a method known as Mendelian randomization to search for genetic relationships between lean muscle mass and genetic variants.

The quantity of lean muscle and fat tissue in the arms and legs was measured using bioimpedance, an electric current that moves through the body at varying speeds. The researchers next discovered 584 genetic variations related to lean muscle mass, but none of these were located in an area of the genome known to include genes connected to an elevated risk of Alzheimer’s disease.

The chance of developing Alzheimer’s disease did, however, appear to be reduced in individuals who had high amounts of lean muscle mass and associated genetic variations.

These results were confirmed by measuring the quantity of lean muscle mass and body fat tissue in a second cohort of 252,879 individuals without Alzheimer’s disease and 7,329 individuals with the condition.

The findings indicated that lean mass was associated with enhanced cognitive performance, but this association did not account for lean mass’s protective effect against the onset of Alzheimer’s disease.

The study’s objectives

The majority of the data utilized by the researchers came from the UK Biobank, a continuous database that collects health and genetic data on 500,000 people. The researchers used data from hundreds of thousands of people.

Mendelian randomization, which employs gene variations as a proxy for specific risk variables, was used to analyze the data.

Additionally, bioimpedance measurements which determine the speed at which an electrical current travels through the body based on its composition in terms of muscle and fat were used to calculate each person’s lean mass.

A total of 584 genetic variations were connected to lean muscle mass, but none of them were discovered in the region of the brain linked to Alzheimer’s susceptibility.

Participants’ chance of developing the disease was statistically significantly (12%) lower on average for those with higher amounts of (genetically proxied) lean muscle.

The analysis was performed using data from an additional 260,208 individuals, of whom 7,329 were identified as having Alzheimer’s disease, in order to confirm these findings. They measured lean muscle mass over the entire body, not only in the arms and legs.

Again, they discovered that having more lean muscle was linked to a lower risk of Alzheimer’s.

Unexpectedly, the analysis did not reveal a correlation between body fat and the probability of developing Alzheimer’s disease once lean mass was taken into account. Body fat was associated with inferior performance in cognitive activities.

The significant contrast between the protective effect of lean mass on dementia risk and the lack of an effect of fat mass on dementia risk, according to Daghlas, startled him.

How Alzheimer’s disease and lean muscle are related?

The fact that the processes underlying the association between lean muscle and Alzheimer’s disease are still unknown is another drawback of the study.

The researchers made brief speculations about possible connections. For instance, Alzheimer’s has long been linked to cardiovascular illness, though Daghlas cautioned that the connection is “complicated.”

According to Daghlas, heart disease problems like stroke and hypertension are what fuel vascular dementia. Though this is a contentious idea, he added, “the most recent causal evidence suggests weaker evidence for an effect of vascular risk factors on Alzheimer’s disease risk.”

Lean mass may very possibly lower the incidence of vascular dementia through lowering the risk of cardiovascular disease, according to Daghlas, however more research is needed in this area. “This can be looked into in upcoming studies.”

In the publication, the researchers also made the speculative claim that “new” processes, such as centrally acting myokines, may be at work.

Myokines are proteins that muscles produce that have an impact on other tissues, according to Daghlas. “Experimental studies have demonstrated that they are induced by exercise and have a positive impact on brain function.”

Other muscle-related issues, in addition to these, “may explain the larger picture,” according to Dr. Anna Nordvig, a neurologist at NewYork-Presbyterian and Weill Cornell Medicine who was not involved in the study. Examples include “bone hormones, cardio vs. strength training differences, sex hormones, glymphatic drainage depending on exercise, and sleep, to name a few.”

In the end, further clinical intervention studies are required to demonstrate the link between lean muscle and Alzheimer’s disease and the mechanisms underlying it.

The best way to build lean muscle mass

Having lean muscle mass has several health benefits in addition to possible advantages for the brain.

Resistance training using weights, bands, and pleiomorphic activities are advised by Dr. Joseph C. Maroon, clinical professor, vice chairman, and Heindl scholar in neuroscience at the Department of Neurosurgery at the University of Pittsburgh.

Additionally, he recommends supplementing with B-hydroxy B-methylbutyrate (myHMB), a good source of dietary protein.

This naturally occurring compound aids in the maintenance of a healthy weight and the development of lean muscle mass in humans. B-hydroxy helps muscles recover from hard activity, improves athletic performance, and enhances muscle and strength, according to him.

According to Dr. Sullivan, the best food, the best kind and frequency of exercise, the optimum amount of rest, and stress management are the primary factors that influence muscle growth.

These are the recommendations she makes:

Exercise: four to five quick strength-training sessions each week. In comparison to two or three longer aerobic exercises each week, this will produce greater lean muscle mass.

Diet: Put your attention on lowering insulin resistance by eating fewer carbohydrates and more protein, the building block of muscle.

Sleep: 8 to 9 hours of sleep per night are recommended if you want to recuperate from this kind of workout completely.

Stress management: With the rise in inflammation and blood sugar that stress hormones like cortisol induce, chronically high stress can sabotage any self-improvement effort. Long-term high cortisol levels can contribute to persistent muscle tension and lactic acid buildup, which can inhibit muscle growth. Moving your body more, going outside, eating more good foods, being an aggressive communicator, and finding your purpose are the simplest ways to relieve chronic stress.

How to lower your risk of developing Alzheimer’s?

Although there is no cure for Alzheimer’s, doctors think there are a number of steps you may take to lower your risk.

“Protect” and “stimulate” are the two categories that these fall under, according to Nordvig, and “physical activity falls into both of these.”

“Protect” includes monitoring factors like blood pressure, sugar levels, weight, nutrition, and sleep, she said. These are topics covered at a yearly checkup.

We should also work to safeguard ourselves from environmental risk factors associated to Alzheimer’s, according to Dr. Rena Sukhdeo Singh, a vascular neurologist at the University of Maryland Shore Regional Health.

The incidence of dementia has also been connected to fine particulate matter in air pollution.

According to Sukhdeo Singh, systemic inflammation also contributes to the development of Alzheimer’s disease. Numerous factors, including medications, a diet high in sugar and processed foods, smoking, and binge drinking, can contribute to chronic inflammation.

Optimising additional daily inputs that influence cognition is what “stimulate” entails. For instance, Sukhdeo Singh proposed, “learning a new skill, hobby, language, or instrument,” or taking part in shorter activities like “sudokus, puzzles, and number games.”

Unfortunately, there are some factors that we have no control over. Age, genetics, and sex are non-modifiable risk variables, she added.

Restrictions of this research

Researchers solely considered lean muscle mass for this investigation. However, there are other things to think about.

The protein amyloid, which is damaging to the functioning of the brain, is found in higher amounts in adipose tissue, but the researchers neglected to test these signs of inflammation and insulin resistance, according to Maroon. “This probably diminishes the significance of their findings.”

Furthermore, “while their positive finding was statistically significant, the effect size was modest in lean muscle mass reducing the risk of dementia and only explained 10% of the variance,” added Dr. Sullivan.

The link between more lean muscle mass and a lower incidence of Alzheimer’s disease has to be further investigated.

According to Nancy Mitchell, a registered nurse, “For now, people with lower muscle mass tend to be obese, which is a risk factor for type 2 diabetes.”

We refer to Alzheimer’s disease as “diabetes of the brain” because it has been hypothesized that high blood sugar harms the nerve endings in the regions of the brain that are most impacted by cognitive decline. Therefore, the link may actually be between a reduced risk of obesity and diabetes. This can be a study drawback in and of itself because greater specificity is still needed. Not all correlations indicate causation. Nancy Mitchell is a nurse practitioner.

REFERENCES:

For Alzheimer’s disease medications that have been suggested by doctors worldwide are available here https://mygenericpharmacy.com/index.php?therapy=31

Can Hormone therapy for menopause increase Dementia risk?

Can Hormone therapy for menopause increase Dementia risk?

Comments 0 Comment

Menopausal hormone therapy is used by about 45% of all women to lessen menopause symptoms.

According to prior studies, some types of hormone replacement treatment may make women more susceptible to developing serious illnesses.

Menopausal hormone therapy is linked to an increased risk of dementia and Alzheimer’s disease, according to researchers from Copenhagen University Hospital, says Rigshospitalet.

These results go against earlier research that suggested HRT might reduce a woman’s risk of dementia.

Menopausal hormone therapy, often known as hormone replacement therapy (HRT), is used by about 45% of all women worldwide to cope with menopause symptoms.

HRT can cause adverse effects like nausea and migraines. According to earlier studies, women who use specific forms of HRT may be more susceptible to strokes, gallbladder problems, and malignancies including breast and endometrial.

Menopausal hormone therapy is now linked to a higher risk of dementia and Alzheimer’s disease, according to study from Copenhagen University Hospital, as per Rigshospitalet.

These results go against earlier research that suggested HRT might reduce a woman’s risk of dementia. The BMJ recently published an article based on this study.

What occurs throughout menopause?

Every woman experiences menopause, which is the end of the monthly cycle and the last time the ovaries release eggs.

Menopause usually begins in a person between the ages of 45 and 55. Perimenopause, often known as the menopausal transition, can persist between seven to fourteen years.

A woman who is beginning menopause may experience symptoms like:

  • a hot flash
  • morning sweats
  • irregular or absent
  • vulvar aridity
  • difficulty sleeping
  • mood swings like anxiousness and depression

Menopause is a natural part of ageing, but it comes with some changes that some people may desire to minimise. Menopause-related symptoms may be treated with the following methods:

  • HRT
  • hormonal birth control at a low dose
  • low-dose mood stabilisers
  • prescription or over-the-counter drugs for vaginal dryness

Additionally, several lifestyle modifications can assist in relieving some symptoms:

  • routine exercise
  • wholesome diet
  • meditation techniques
  • restricting alcohol
  • giving up smoking
  • counselling for mood changes
  • maintaining a healthy sleep routine

What is hormone therapy for menopause?

The purpose of HRT is to enhance and balance the levels of the female hormones progesterone and oestrogen in the body.

Although the body’s ovaries naturally produce both of these hormones, their production declines after menopause, leading to menopausal symptoms.

There are two primary types of menopausal hormone treatment that a doctor could recommend, depending on a woman’s situation and requirements:

  • treatment with just oestrogen
  • combined treatment utilising progesterone and oestrogen

HRT can be applied topically or vaginally, and comes in tablet, nasal spray, skin patch, and vaginal cream or suppositories forms.

The following are possible HRT adverse effects:

  • bloating
  • headaches
  • breast discomfort
  • nausea
  • acne
  • mood changes
  • uterine bleeding

How Does HRT Affect the Risk of Dementia?

Dr. Nelsan Pourhadi, the study’s lead author and a researcher at the Danish Cancer Society and the Danish Dementia Research Centre in the Department of Neurology at Copenhagen University Hospital – Rigshospitalet in Copenhagen, Denmark, claims that the study’s objectives were dual and based on understudied facets of the subject matter.

“First, we sought to look into whether menopausal hormone therapy use, as advised by guidelines, increased the incidence of dementia.” Second, he told us, “we were looking into continuous versus cyclic therapy regimes.”

Dr. Pourhadi and his team used data from a national registry database for this investigation. The study’s controls were about 56,000 age-matched women without a dementia diagnosis and approximately 5,600 women with dementia. Danish women between the ages of 50 and 60 in 2000 who had no history of dementia or any conditions that would exclude the use of HRT were included in the data, which covered the years 2000 to 2018.

The subjects’ average age at the time of dementia diagnosis was 70. In comparison to controls, 32% of women with dementia and 29% of controls had used estrogen-progestin therapy starting at an average age of 53 before receiving a diagnosis. For dementia-stricken women, therapy lasted an average of 3.8 years, compared to 3.6 years for males.

Analysis revealed that women who got estrogen-progestin therapy had a 24% higher incidence of Alzheimer’s disease and all-cause dementia. Even ladies who started the treatment at age 55 or younger experienced this.

The Women’s Health Initiative Memory Study (WHIMS), the largest clinical experiment in the field, found similar results, according to Dr. Pourhadi.

Does HRT alter the risk of dementia?

Researchers have previously searched for a link between HRT and the risk of dementia.

Menopausal hormone therapy may aid in lowering a woman’s risk of dementia, according to earlier studies. Menopausal hormone therapy use was associated with a lower chance of developing all neurological disorders, including Alzheimer’s disease and dementia, according to a study released in May 2021.

Additionally, a study published in June 2022 discovered that women with depression who used HRT after menopause had a lower risk of developing Alzheimer’s disease and vascular dementia.

Several research have shown a connection between HRT use and an elevated risk of dementia. HRT was linked to a higher incidence of dementia, according to research released in September 2022.

And according to a study that was just released in April 2023, women who had HRT more than five years after the onset of menopause or who started menopause early had greater levels of tau protein in their brains, which is thought to be one of the main causes of Alzheimer’s disease.

When questioned why prior and current studies may have conflicting results, Dr. Pourhadi responded, “It is crucial to emphasise that our findings are in line with those of the largest clinical trial on the topic, WHIMS. The majority of prior clinical trials were hindered by issues like poor selection, limited sample sizes, brief follow-up periods, and results that were purely dependent on cognitive testing rather than a clinical evaluation of dementia.

Furthermore, earlier observational studies, particularly short-term ones, were unable to evaluate the use of menopausal hormone therapy close to menopause, the author continued. The discrepancies between the findings of those studies and those of our study “may be explained by these differences.”

Can HRT lead to dementia?

Dr. Pourhadi explained that because this study is an observational one and not a causal one, it is impossible to establish a link between menopause hormone therapy and dementia.

Therefore, more investigation is required to determine whether or not the observed link may be assumed to be causal. Additionally, it is important to distinguish between the various menopausal hormone therapy delivery methods such as tablets, patches, and gels,” he continued.

Dr. Mindy Pelz, a specialist in holistic medicine who specialises in women’s and hormonal health but was not part in this study, concurred.

It’s vital not to overestimate the results of this new observational study. Correlation does not imply causality, and prior research has shown that menopausal hormone therapy lowers the incidence of dementia, so it’s conceivable there’s a variable missing that we haven’t thought of yet, the researcher added.

She told us that many women go for hormone replacement medication to deal with their symptoms when they have cognitive deficiencies after menopause, which could be a sign of dementia in the future.

Dr. Jewel Kling, assistant director of women’s health internal medicine at the Mayo Clinic in Arizona and a non-participant in this study, informed us after reviewing the findings that because this was an observational study using data from a national registry, we could not draw any conclusions about the cause-and-effect relationship between menopausal hormone therapy and dementia risk.

The only way to conclude causation is through a randomised control design, which this wasn’t. “(We) can only claim that there was a relationship identified between the two in their data. According to the study’s design, there are numerous additional factors that could potentially explain this association, the researcher said.

REFERENCES:

For Mental disease medications that have been suggested by doctors worldwide are available here https://mygenericpharmacy.com/index.php?cPath=77_478

Can you prevent heart attack with monthly Vitamin D dose?

Can you prevent heart attack with monthly Vitamin D dose?

Comments 0 Comment

A crucial fat-soluble vitamin for supporting the immune system and bone health is vitamin D. Australian researchers monitored a group of elderly individuals. This is to determine whether vitamin D supplements could lower the incidence of serious heart disease events.

For five years, the test group received a monthly vitamin D supplement from the researchers.

The participants who took vitamin D supplements did have a slight risk decrease for several major cardiovascular events, even though it was not as significant as the researchers had hoped.

According to a study that was recently published in the BMJ, an Australian research team conducted a clinical trial. This was to see if vitamin D may help prevent major heart disease events like heart attacks and strokes.

The older persons were tracked by the researchers between the ages of 60 and 84. Heart disease is thought to be more likely to strike people in this age bracket.

When comparing the control and test groups, the researchers found that vitamin D had no effect on strokes. However, they did discover that the rate of major cardiovascular events was 9% lower in the vitamin D supplement group.

What is Vitamin D?

In addition to supporting the immune system and other processes, vitamin D is crucial for strong bones. The human body responds to sun exposure by producing vitamin D. A person can increase their vitamin D intake by eating particular foods or taking supplements.

For strong bones and teeth, vitamin D is necessary. In addition, it performs a variety of other crucial functions in the body, including controlling immunological response and inflammation.

Despite its name, vitamin D is actually a hormone or prohormone rather than a vitamin.

Detailed research on vitamin D

The leading cause of death in the United States is cardiovascular disease (CVD). Although CVD can affect adults of any age, those 65 and beyond have the highest illness rates.

CVD can be dangerous and may be and the potential strain it may have on the healthcare system. Researchers have been exploring strategies to both treat and prevent the illness.

The authors of the study noted that earlier studies had limitations and did not demonstrate a link between vitamin D and lowering the risk of CVD. Because of the author’s observation, vitamin D has biological effects which suggest it could influence cardiovascular disease. Therefore, they conducted a more thorough investigation.

21,315 participants in the study ranged in age from 60 to 84. Participants who were already taking vitamin D supplements or had a history of diseases like sarcoidosis and hypercalcemia were excluded from the study.

A 60,000 IU vitamin D-3 pill was given to the test group once a month for five years. The control group consumed a sugar pill.

In order to understand the individuals’ socioeconomic level, way of life, and eating habits, the researchers gathered baseline data. They collected surveys, tested blood samples, and kept an eye out for adverse events throughout the trial. This is to ensure sure the participants were taking their supplements as prescribed.

The individuals also allowed researchers access to their medical records. So that they could gather data on mortality, prescribed drugs, and cardiovascular events.

Does vitamin D aid the heart?

A few previous observational studies have hinted at a potential link between reduced incidence of CVD and higher blood levels of vitamin D.

This new study suggests that vitamin D supplementation may have some advantages, even if clinical studies have not yet conclusively shown that it improves heart health.

When compared to the placebo group, the number of heart attack events among people taking vitamin D was 19% lower. Additionally, the vitamin D group had decreased rates of coronary revascularization, which might involve treatments like a heart bypass or a coronary artery bypass graft.

Although the rate of major cardiovascular events was 9% lower overall in the groups receiving vitamin D, the study’s results did not indicate a lower rate among minor cardiovascular events.

The scientists cautioned about the 9% decline, saying it’s likely that users of statins or other cardiovascular medications may have contributed to it.

“For total major cardiovascular events, there was some indication of a stronger effect in those who were using statins or other cardiovascular drugs at baseline,” the authors wrote.

Because of this, the authors state that additional research is necessary before they can state with certainty that vitamin D alone prevents CVD.

The authors conclude that their research “indicates that supplementation with vitamin D may reduce the incidence of major cardiovascular events, particularly myocardial infarction, and coronary revascularization.”

“Those who were taking statins or other cardiovascular medications at the outset may have noticed this beneficial impact more clearly. The authors write, “Subgroup studies in other major trials might assist to explain this issue.

Does vitamin D suffice to lower the risk of CVD?

We had a discussion about the study with Dr. Yu-Ming Ni, a cardiologist from MemorialCare Heart and Vascular Institute at Orange Coast Medical Centre in Fountain Valley, California. Dr. Ni did not believe that the study’s findings were yet significant enough to demonstrate that vitamin D supplementation can lower rates of CVD.

“After reading this study, it is tempting to draw the conclusion that there may be a trend towards a benefit for vitamin D supplementation for the prevention of cardiovascular disease, especially as it relates to the prevention of heart attacks myocardial infarction,” he stated.

According to Dr. Ni, the new study “did not demonstrate a significant benefit of Vitamin D supplementation, even if there was a small benefit” when compared to previous studies on vitamin D and CVD.

Dr. Ni stated that vitamin D is still an essential supplement for bone health even though she did not believe the study offered hope for using it to lower the incidence of CVD.

When we discussed the report with Dr. Dmitriy Nevelev, associate director of cardiology at Staten Island University Hospital in New York, he had a somewhat different perspective on it.

Dr. Nevelev added that although earlier sizable studies on vitamin D and CVD had not revealed a “significant effect,” “many of these studies had limitations such as suboptimal adherence with daily therapy, an insufficient dose of vitamin D, or an overall lower risk population.”

REFERENCES:

For Heart disease medications that have been suggested by doctors worldwide are available here https://mygenericpharmacy.com/index.php?cPath=77_99

Once-weekly insulin vs daily injection: Which is better?

Once-weekly insulin vs daily injection: Which is better?

Comments 0 Comment

The effectiveness of once-weekly and once-daily insulin therapy for type 2 diabetes was compared by researchers.

They discovered that the once-weekly medication icodec reduced blood sugar levels more successfully than the conventional once-daily injections.

Further research is required, according to experts, to validate the findings. A novel, once-weekly insulin regimen may revolutionize care for type 2 diabetics, finds a recent study.

In a Phase 3 experiment, researchers compared the effectiveness and safety of once-weekly insulin termed “icodec” with the conventional once-daily injection degludec in adults with type 2 diabetes.

A long-acting insulin medication called Degludec aids in controlling blood sugar levels.

After 26 weeks, they discovered that once-weekly icodec therapy reduced blood sugar levels more than once-daily degludec. The research was released in JAMA.

Icodec may have similar glucose-lowering effects to daily insulin injections, according to a recent study.

Adherence issues with daily insulin injections

In the US, there are more than 37 million diabetics. These persons have type 2 diabetes in 90–95% of cases.

The hormone insulin, which is produced by the pancreas, enables cells to utilise glucose as fuel. When cells no longer react to insulin as they should, type 2 diabetes develops and elevated blood sugar levels follow.

The eyes, kidneys, and heart are just a few of the organs that elevated blood sugar can harm over time. Therefore, either lifestyle changes or the use of drugs that do not lower blood sugar with insulin is required for treatment.

When non-insulin treatments are ineffective, it is currently recommended by guidelines that persons with type 2 diabetes take insulin-based therapies to reduce blood sugar levels.

Currently, type 2 diabetes medications based on insulin necessitate daily injections. However, patients may find it difficult to administer daily injections, which lowers adherence rates.

According to research, weekly injections increase adherence. According to one study, individuals who receive insulin treatments once per week follow their treatment plans for an average of 333 days as opposed to 269 days for patients who receive daily injections.

Insulin therapy non-compliance might have serious repercussions. According to research, persons with diabetes who do not stick to their insulin medication have a higher risk of dying and being admitted to the hospital.

Thus, raising adherence rates is essential to enhancing diabetes patients’ quality of life and health outcomes.

Which is more effective? Once-weekly vs. daily insulin injection.

The researchers gathered 588 participants for the study, with an average age of 58, from 11 nations, including the USA, Argentina, and China.

Over a third of the participants were women, and every participant was on non-insulin glucose-lowering medication.

They were thereafter randomly assigned to receive one of the following treatment plans for a total of 26 weeks during the study:

  • once every week icodec
  • monthly placebo
  • every day degludec
  • a single-dose placebo

In the end, the scientists discovered that icodec more effectively lowered haemoglobin A1c (HBA1c) levels than degludec.

A measurement of the average blood sugar levels over the previous three months is called HBA1c. Those with diabetes are advised to maintain levels of 6.5% or lower. People without diabetes typically have HBA1c values of less than 5.7%.

Participants in the icodec group had HBA1c values that dropped from an average of 8.6% to 7% after 26 weeks. HBA1c values in the degludec group decreased from an average of 8.5% to 7.2% over this time.

The study’s authors found no discernible differences in participants’ fasting blood sugar levels or body weight between those taking icodec and those taking degludec.

We enquired about the potential causes of icodec’s superior results in lowering HBA1c readings from Dr. Absalon Gutierrez, associate professor of endocrinology at McGovern Medical School at UTHealth Houston who was not engaged in the study.

Although we can’t be certain, it probably has to do with the patient’s compliance with the drug. According to how the trial was set up, it was significantly simpler to forget to administer the degludec injections than the icodec injections. According to Dr. Gutierrez, this is most likely the case in real life as well.

Side effects of icodec weekly insulin

The researchers also reported that from the beginning of the study until week 31, 5.8% of those using Degludec and 8.9% of those taking icodec suffered hypoglycemia. This is characterized by blood sugar levels that are below the normal range.

Additionally, during the duration of the experiment, 167 patients receiving degludec and 177 patients getting icodec both had adverse effects. According to the researchers, 46 and 60 incidents, respectively, were in the degludec group and the icodec group. This may have been caused by the use of insulin.

However, they pointed out that the majority of the incidents were minor, and that these included COVID-19, influenza, and diabetic retinopathy, an eye disorder that can impair vision in people with diabetes.

What are the research’s constraints?

The study’s shortcomings were listed by the researchers in their paper. They pointed out that because the trial only lasted 26 weeks, longer-term consequences are still undetermined.

They also stated that they did not gather information on patient-reported outcomes or data from continuous glucose monitoring.

Dr. Gutierrez stated: “Icodec exhibited higher hypoglycemia even though it worked somewhat better in decreasing HBA1c. Given that it can’t be titrated as regularly, this is to be expected. Additionally, the degludec titrations were not ideal according to the study’s design.

Dr. Lushun Wang, Senior Consultant Orthopaedic Surgeon and Medical Director of Arete Orthopaedic Clinic in Singapore and a non-participant in the study, was also interviewed by us:

“The trials’ duration can be extended further in order to guarantee dependable long-term efficacy and safety. To comprehend Icodec more fully, rigorous and in-depth testing should be conducted.

Data from continuous glucose monitoring may ensure a more thorough understanding of blood glucose control and its impact on the quality of life of the patient. In addition, the trial’s design used more Icodec injections than would be necessary for a daily regimen, which does not adequately reflect real-world use or any potential advantages for treatment adherence.

Effects of once weekly injection on diabetes

The researchers observed that by lowering the number of injections from at least 365 to 52 annually, icodec may increase treatment adherence and convenience for individuals with type 2 diabetes.

They went on to say that the “small absolute risk of hypoglycemia” should be outweighed by the ease and little additional glycemic advantage of once-weekly dosing.

Icodec’s practical design enables daily injections to be replaced with this once-weekly alternative, according to Dr. Wang. Its main benefit is from its capacity to deliver an insulin release that is steady and continuous over the course of a week. Hence minimizing swings in blood glucose levels. The improved HbA1c reduction seen in the studies is evidence that Icodec’s ability can result in better overall blood glucose control.

Dr. Guitierrez concurred that icodec insulin would be a viable choice for patients who struggle to take once-daily basal insulin as prescribed. To better understand the risk of hypoglycemia associated with using icodec in comparison to once-daily insulin injections, he pointed out that more research is required.

REFERENCES:

For Diabetes medications that have been suggested by doctors worldwide are available here https://mygenericpharmacy.com/index.php?therapy=13

MS severity: Genetic markers may lead to better treatment.

MS severity: Genetic markers may lead to better treatment.

Comments 0 Comment

Globally, 2.8 million people will have Multiple Sclerosis (MS) in 2020. The symptoms of MS can worsen over time and result in chronic problems, and the condition presently has no known cure.

The first genetic indicator of MS severity and progression has been identified by researchers at the University of California, San Francisco.

This discovery, according to scientists, may help in the creation of new medications that can delay the advancement of the illness.

Multiple sclerosis (MS), a condition of the central nervous system that affects mobility and vision, will impact roughly 2.8 million individuals worldwide by the year 2020.

MS presently has no known cure. Each person is uniquely affected by the illness, both in terms of when symptoms initially appear and how severe they are.

The severity of the illness can worsen as the body experiences a cycle of symptom flare-ups and remissions, resulting in persistent mobility problems, visual loss, and even partial or complete paralysis.

The first genetic signature connected to MS severity and progression has now been identified by researchers from the University of California, San Francisco.

This discovery, according to scientists, may help in the creation of new medications that can delay the advancement of the illness.

Research targets MS progression

The University of California, San Francisco’s Dr. Sergio Baranzini, professor of neurology and co-senior author of the study, explained that they chose to look for a genetic variation associated with faster MS progression because the disease develops differently in each patient after diagnosis.

“Neurological progression is a common feature in persons with MS, which is inexorable and independent of whether relapses are controlled or not,” he said.

“Some people have a very aggressive disease that can impact their mobility and neurological function in a few years, while others experience a much more benign course,” he said. We already knew that genetics has a significant influence on risk, but the wide range of outcomes revealed that genetics may also affect severity.

Data from The MultipleMS Consortium and The International Multiple Sclerosis Genetics Consortium (IMSGC), two sizable MS research consortiums, were used by Dr. Baranzini and his team.

For a genome-wide association study (GWAS), data from both groups were pooled to represent more than 12,500 MS patients.

From there, researchers combed through more than 7.5 million genetic variants before discovering one linked to accelerated disease progression in MS patients.

This particular mutation is situated between two genes named DYSF and ZNF638 that had no known association with MS. ZNF638 aids in the control of viral infections whereas DYSF aids in the restoration of damaged cells.

Possibility of new treatments for MS

Since there is currently no treatment for MS, doctors employ a variety of drugs to treat the symptoms, delay the disease’s course, and help avoid relapses.

The results of this study, according to Dr. Baranzini, will open the door for a new class of medicines that will treat progression and probably target the central nervous system.

Dr. Baranzini made the point that genetic information considerably reduces the risks associated with drug development because developing medicines represents a considerable risk for the pharmaceutical business, where only a tiny percentage of drugs reach the market.

“This discovery will set up several development programs that will target the unmet need of disease progression in MS,” he said.

“All relapse-controlling medications are immunomodulatory, which is consistent with the genetics of the more than 200 MS risk variations. The central nervous system should be the target of this new class of therapies, according to the genetics of illness severity.”

Dr. Baranzini explained that since it has been proven that genetics contribute to the severity of an illness, the IMSGC is currently preparing for a new genetic study including even more participants.

The researcher continued, “Our prior experience with disease susceptibility suggests that a larger study translates into more findings, and we are pleased to uncover new genetic variants that could aid in the development of more efficient treatments for MS.”

How is MS being treated right now?

The capacity to move, think, talk, and see clearly can all be significantly impacted by MS since it affects the brain and nerve system.

The majority of scientists concur that MS is caused by the body’s immune system wrongly attacking the central nervous system, even though the exact origin of MS is still unknown.

The myelin that wraps the nerve fibres in the brain and spinal cord is damaged by this onslaught. When myelin is destroyed, it is unable to protect the exposed nerve fibre, which prevents messages from travelling from the nerves to the brain.

Additional MS risk factors include:

  • age – between the ages of 20 and 50, most persons acquire a diagnosis
  • MS is more prevalent in women than in men.
  • an MS family history
  • smoking
  • a lack of vitamin B12 or vitamin D
  • exposure to specific viral illnesses, such as mononucleosis or the Epstein-Barr virus

Why the recent study is beneficial?

We discussed the significance of the study with Dr. Krupa Pandey, director of clinical research at the Neurosciences Institute in New Jersey, director of the Hackensack University Medical Centre MS Centre, and associate professor of neurology at the Hackensack Meridian School of Medicine who was not involved in the current investigation.

She said, “There are a few ways in which this study is helpful. Finding a connection between genes and the potential severity of a disease is a positive step.”

“It is also beneficial since it offers more proof that environmental variables, like smoking, truly do assist people with genetically susceptible diseases to get sicker. This is a fantastic illustration of how a disease may be affected by both nature and upbringing, said Dr. Pandey.

The expert went on to say that similar discoveries “may lead to future findings that can help us counsel patients on how to tailor not just medication regimens but modify lifestyle-related factors.”

“It is also helpful for companies looking at MS therapies [to] enroll patients with higher risks for progression to see if the drug is effective,” she said.

REFERENCES:

For Nerve damage medications that have been suggested by doctors worldwide are available here https://mygenericpharmacy.com/index.php?cPath=30

Coffee: Is it energy booster or just a placebo?

Coffee: Is it energy booster or just a placebo?

Comments 0 Comment

The neurological effects of caffeine and coffee consumption were compared by researchers. They discovered that drinking coffee, but not caffeine, enhances brain activity associated with higher-order cognitive function and visual processing.

Could the effects of coffee on enhancing focus and performance be a placebo effect? A recent study comparing the impact of drinking coffee vs only caffeine suggests that might be the case.

Coffee is frequently consumed first thing in the morning to combat fatigue, maintain alertness, and perform well. Approximately 49% of Americans who are 20 years of age and older and who drink coffee do it daily.

Several distinct chemicals in coffee have diverse effects on the brain. The most well-known of these substances, caffeine, is known to stimulate dopamine circuits that improve memory.

Coffee’s neurochemical effects on the brain are well established, but its psychological consequences are less well understood.

For instance, some study indicates that while coffee consumption may have an impact on cognitive function in non-regular drinkers, it has less of an impact on habitual drinkers due to tolerance development.

According to the same research, a significant portion of caffeine’s and coffee’s stimulating effects may be accounted for by the alleviation of withdrawal symptoms following brief abstinence.

It may be easier to comprehend why individuals consume coffee with the help of more research into how coffee affects the brain.

They discovered that the effects of caffeine and coffee on brain function altered “the connectivity of the default mode network.” This shows that caffeine or coffee consumption facilitated the shift from resting to working on tasks, according to a news release.

Active ingredients in coffee

Numerous bioactive substances found in coffee contribute to its potential for substantial health effects.

Many of these substances are antioxidants, which protect your cells from injury from dangerous free radicals.

The key components of coffee are listed below:

  • Caffeine. Caffeine, which is coffee’s primary active component, activates the central nervous system.
  • Acids chlorogenic. Some biological pathways, including blood sugar metabolism and high blood pressure, may benefit from these polyphenol antioxidants.
  • Cahweol and cafestol. These substances are abundant in unfiltered coffee and are present in the natural oil of coffee.
  • Trigonelline. Since this alkaloid molecule is unstable at high temperatures, it transforms into nicotinic acid, or niacin (vitamin B3), during roasting.

However, the concentrations of these ingredients in a cup of coffee can differ.

Effects of drinking coffee as opposed to only caffeine

47 participants who consumed at least one cup of coffee daily were chosen by the researchers for the study. 31 of them were female, and they were all around the age of 30.

Before taking part in the trial, each participant was instructed to refrain from consuming any caffeinated food or beverages for at least three hours.

The subjects were subjected to two fMRI scans in the lab: one before and one 30 minutes after ingesting caffeine or drinking a cup of coffee. Participants were instructed to unwind and allow their thoughts wander throughout the fMRI scans.

In the end, the researchers discovered that in the default mode network (DMN), both coffee and caffeine decreased functional connectivity.

According to the authors, “self-referential processes when participants are at rest” are connected to the DMN. Reduced DMN, according to the researchers, suggests a higher level of readiness to shift from resting to task-context processing.

They also observed that consumption of coffee, but not caffeine, markedly reduced brain connection between somatosensory and motor networks. This may help to explain why people report having better psychomotor function after consuming caffeinated coffee, according to the researchers.

The executive control and visual networks associated with visual processing and higher-level cognitive function, such as working memory, cognitive control, and goal-directed behaviour, were more active after coffee consumption but not caffeine.

Coffee consumption is a sensory experience.

The researchers hypothesised that the sensory experience of drinking coffee may be the cause of the different effects of ingesting caffeine and drinking coffee.

The additional effects of drinking coffee may be explained by the placebo effect, according to Armargo Couture, a registered dietitian nutritionist at Staten Island University Hospital in New York who was not involved in the study:

Because drinking a cup of coffee in the morning is the social custom in this culture, the placebo effect may be effective in this situation. In essence, many people connect their “morning coffee” with “waking up” and getting ready for the day.

“Many people regularly take their morning cup of coffee after getting out of bed before beginning the day, which naturally comes to be connected with being successful. The idiom “don’t talk to me until I’ve had my morning coffee” was coined because preparing for the day with a daily cup of coffee is a shared experience and the social norm, she continued.

However, Couture pointed out that other substances in coffee may potentially be the source of its additional effects.

“Coffee’s terpenes, cafestol and kahweol, and polyphenols, including chlorogenic acids, interact with different brain receptors to boost energy, elevate mood, and instill a motivational attitude. According to a study, coffee’s terpenes and polyphenols contain anti-inflammatory and antioxidant effects that have also been linked to a lower incidence of depression.

Study limitations for evaluating the effects of coffee

Dr. Teixeira pointed out that the study’s significant shortcomings include the absence of non-drinker or decaf-drinker groups as well as the absence of task-related fMRI data or cognitive tests.

“Rather of directly measuring cognitive function, the researchers used fMRI to examine brain connections. The lay media frequently misinterprets things like this, he said.

“It is also unclear how matched the coffee and caffeine groups were regarding sociodemographic and coffee and/or other caffeinated beverage consumption,” he continued.

We also received the following information from Dr. Gregory S. Carter, Ph.D., Associate Professor of Neurology and Head of the Sleep Medicine Section for the Department of Neurology at the University of Texas (UT) Southwestern Medical Centre.

The length of time between consuming coffee or other caffeinated beverages and the fMRI’s operation is the main restriction. The caffeine that has been dissolved takes 50–60 minutes to reach its peak blood concentration. The authors tested after 30 minutes, which is a little early especially when the blood-brain barrier’s relatively swift transit is taken into account.

The results are further constrained, according to Dr. Michael J. McGrath, Medical Director at the Ohana Luxury Alcohol Rehab and a board-certified psychiatrist who was not involved in the study, because the researchers did not examine whether the advantages coffee drinkers enjoy are caused by the alleviation of withdrawal symptoms.

Benefits of coffee consumption

According to Couture, “coffee may benefit your mindset towards goals while improving your working memory and cognition. It increased subjects’ executive control.”

She continued, “Those who struggle with executive dysfunction may find that consuming coffee helps by boosting motivation and working memory.

Dr. McGrath added that the findings demonstrate that some advantages of drinking coffee derive from sources other than caffeine. He pointed out that this suggests that consuming decaffeinated coffee in the morning may help increase alertness and focus.

REFERENCES:

For Energy booster medications that have been suggested by doctors worldwide are available here https://mygenericpharmacy.com/index.php?therapy=83

Is Mirikizumab useful for ulcerative colitis as per study?

Is Mirikizumab useful for ulcerative colitis as per study?

Comments 0 Comment

In a recent clinical trial, a novel drug being developed to treat ulcerative colitis showed promise.

Researchers found that those receiving the medication lebrikizumab experienced remission from ulcerative colitis twice as frequently as those taking a placebo.

The results, according to experts, are encouraging; nonetheless, more clinical trials are required because the medicine has not yet received approval from federal regulators.

Research in the New England Journal of Medicine found that people receiving the medication lebrikizumab experienced remission from ulcerative colitis almost twice as frequently as those taking a placebo.

Researchers examined the effectiveness and safety of lebrikizumab, a novel injectable drug being created to treat ulcerative colitis. The use of lebrikizumab in the US has not yet received approval from the Food and Drug Administration.

In comparison to those who took a placebo, participants reported having a better clinical response, endoscopic remission, and reduced urgency in bowel movements.

Clinical studies for a new medication for ulcerative colitis

52 weeks of treatment were spread across two phase 3 double-blind, placebo-controlled trials. 1,281 adults with ulcerative colitis who had moderate to severe inflammation participated in the experiment.

LUCENT-1, the first, ran for 12 weeks. Three participants received 300 mg of lebrikizumab for each one who received a placebo. 294 patients received a placebo, whereas 868 patients received lebrikizumab.

The maintenance phase, LUCENT-2, was continued with the participants who were deemed receptive. Rectal haemorrhage and stool frequency were measured by the researchers.

At the conclusion of the 12-week period, 179 placebo patients and 365 mirikizumab users both reported responsiveness.

Participants were given a 200 mg dose of mirikizumab or a placebo during the second stage, which is known as the maintenance phase.

Nearly 50% of those who got mirikizumab and 25% of those who received a placebo experienced remission by week 40 of the maintenance phase (or by week 52 of both phases combined).

Eli Lilly, a pharmaceutical corporation, supported the research.

Expert response to medication research for ulcerative colitis

Longer trials are being conducted to evaluate the safety and efficacy of mirikizumab over longer periods of time.

“This study shows that we have another tool for people with ulcerative colitis and that this might help those who do not respond to other medications,” said Dr. Ashkan Farhadi, a gastroenterologist at MemorialCare Orange Coast Medical Centre in California who was not involved in the study. However, I’m not giddy with excitement over the figures.

And before we can get this to the patients, it will be a while. The phase 4 trial comes first. We have the insurance companies to get through if that advances us to the next round, Farhadi said.

“These medicines are outrageously expensive, and insurance companies frequently need us to pass hurdles before receiving clearance. For instance, they might advise the patient to try several other medications first,” he continued.

“In general, I believe having additional tools is a good thing. However, the numbers do not now make this my top pick, said Farhadi.

Ulcerative colitis: What is it?

A chronic inflammatory bowel illness is ulcerative colitis.

It is regarded as an autoimmune condition that affects the lining of the colon and rectum and results in sores and ulcers.

The signs consist of:

  • Diarrhea
  • stool with blood in it
  • Continent pain

The condition ulcerative colitis cannot be cured. The Crohn’s & Colitis Foundation lists the following as treatments:

  • drugs that reduce inflammation
  • biologics
  • immunomodulators
  • a variety of drugs taken together
  • surgery

During a flare, doctors also advise sticking to a diet of soft, bland foods. They could advise cutting back on hot and high-fiber foods as well.

How drugs can treat ulcerative colitis?

According to the American Academy of Family Physicians, when ulcerative colitis patients take medication, remission occurs in about two-thirds of cases. 80 percent of them will continue to be in remission.

Dr. Arun Swaminath, chief of gastroenterology and director of the Inflammatory Bowel Programme at Northwell Lenox Hill Hospital in New York, who was not involved in the study, said, “This is very difficult to understand.” “Response rates for other autoimmune diseases, like rheumatoid arthritis, range from 80 to 90 percent. But because of ulcerative colitis, we cannot travel there. It’s possible that the reason why inflammatory bowel diseases (IBD) have such a high burden of inflammation.

The release of a new IBD drug always excites medical specialists. According to Swaminath, the mechanism of action for mirikizumab is distinct. Its physiological effects will be different from those of other drugs.

“There are some positives, such as the fact that this study enrolled many people in the severe category,” he continued. “It is challenging to determine how much the medication works when studies mostly include people in the moderate category. I was quite inspired to learn that participants with advanced illnesses still experienced success.

What’s coming up in medication research for ulcerative colitis?

A phase 3 experiment was the current investigation. According to the National Cancer Institute, phase 3 trials examine a new drug’s safety as well as how well it performs over a longer time frame than in earlier trials.

A phase 4 clinical trial would presumably follow the FDA’s approval of mirikizumab. Thousands of participants frequently participate in phase 4 trials.

The next phase “might answer some lingering questions” because so many more people will be involved, according to Swaminath. “For instance, while I read the paper, I pondered the situation of those who had previously taken Stelara. Does the fact that they were rejected from phase 3 indicate that they won’t be suitable candidates for this medication? In addition, there were two cases of induction-phase cancer and two cases of maintenance-phase cancer. Were those cancers prevalent at the time? To learn what transpires when the drug is administered to a big population, we must monitor the subsequent phase.

REFERENCES:

For Ulcerative colitis medications that have been suggested by doctors worldwide are available here https://mygenericpharmacy.com/index.php?therapy=69

Important signs to consider to avoid Colorectal cancer.

Important signs to consider to avoid Colorectal cancer.

Comments 0 Comment

The incidence of colorectal cancer, which ranks third among all cancers in the globe, is on the decline in older people and is largely avoidable. However, the prevalence of colorectal cancer among younger people is rising.

Seven risk factors that raise the likelihood of colorectal cancer in younger males have been found in a recent study. Men under 45 who are at increased risk should get screened for colorectal cancer, according to the authors.

Colorectal cancer is the third most prevalent cancer in the world, behind breast and lung cancer. Only lung cancer accounts for more fatalities. It is estimated that each year, more than 150,000 people in the United States alone receive a colorectal cancer diagnosis.

The median age of diagnosis for colorectal cancer is 66, and persons over the age of 45 are most likely to develop it. According to the American Cancer Society, widespread screening of adults over 50 and the removal of pre-cancerous growths known as polyps are contributing to a decline in colorectal cancer occurrences and deaths in older people.

Those under 45 have a low chance of developing colorectal cancer, the number of cases and fatalities in this age group has been rising since the 1990s.

Currently, a research of American veterans has identified certain elements that are linked to a higher risk of early-onset colorectal cancer in males. The authors contend that in some situations, targeted screening may aid in case prevention.

What exactly is colorectal cancer?

Cancer that starts in the colon or rectum is called colorectal cancer. These cancers may also be known as colon cancer or rectal cancer depending on where they first appear.

The majority of colorectal malignancies begin as polyps, which are growths on the colon’s inner lining. Even though not all polyps develop into cancer, some of them can over time.

In the United States, colorectal cancer ranks third among all cancers, excluding skin cancer, according to the American Cancer Society.

Causes of colorectal cancer risk

The researchers located 956 men between the ages of 35 and 49 who had received a non-hereditary colorectal cancer diagnosis between 2008 and 2015 from the National Veterans Affairs database in the United States. 600 of them satisfied the requirements for study inclusion.

These were then matched with 1,200 controls who underwent colonoscopies but did not develop colorectal cancer and 1,200 controls who had not.

For both cases and controls, the researchers examined sociodemographic and lifestyle characteristics, family and personal medical histories, physical measurements, vital signs, medications, and laboratory results. For people with colorectal cancer, data from the six to eighteen months before diagnosis were utilized to identify characteristics that might vary with the development of the disease.

Age, cohabitation, employment, BMI, malignancies in first- or second-degree relatives, comorbidities, alcohol use, hyperlipidemia, and usage of statins, non-steroidal anti-inflammatory medications (NSAIDs), or multivitamins were all examined to find risk variables.

From this, scientists discovered 15 variables that were each independently linked to a higher chance of developing colorectal cancer at an early stage. They singled out seven of these that offered equivalent precision and whose data are easily obtainable:

  • elder age (between the ages of 35 and 49)
  • NSAIDs (such as aspirin or ibuprofen) should not be regularly used.
  • no consistent statin use
  • usage of alcohol today
  • relatives in the first or second degree who have colorectal cancer
  • a greater burden of sickness

According to corresponding author Dr. Thomas F. Imperiale, a research scientist at the Regenstrief Institute, several characteristics raised risk more than others:

It was more significant to have a first- or second-degree family who had colorectal cancer. Non-steroidal anti-inflammatory drug use and statin use were two additional factors with a stronger impact.

Risk of colorectal cancer and lifestyle

The risk of colorectal cancer may be increased by a number of lifestyle variables, according to the Centres for Disease Control and Prevention (CDC). These consist of:

The study’s author, Dr. Bilchik, who was not involved in it, emphasized the importance of lifestyle factors:

According to this study, lifestyle choices have a significant impact on the development of colorectal cancer. For instance, taking statins is connected to elevated cholesterol, and food and alcohol have also been linked to a number of different cancers.

Screening for high-risk individuals

The researchers pointed out that although their study only included men, men are still twice as likely to develop colorectal cancer as women of any age. However, they are currently conducting research along these lines on female risk factors.

They emphasised that not all younger men should have colorectal cancer screenings, but those who are at higher risk may benefit.

“Only high-risk men between the ages of 35 and 44 should be screened. Guidelines now recommend colorectal cancer screening for men between the ages of 45 and 49 but do not specify how (i.e., which test),” Thomas F. Imperiale, M.D.

“The risk factors may be helpful in deciding whether noninvasive testing (with the faecal immunochemical test or with the multi-target stool DNA test) or a colonoscopy is more appropriate,” Dr. Imperiale said to us.

Additionally, he hoped that highlighting these risk factors will prompt males between the ages of 45 and 49 who are already eligible for screening to request testing.

The findings indicating that colorectal cancer screening is advised starting at age 45 are particularly pertinent to male veterans under the age of 35. Dr. Imperiale continued, “However, the results may also be valuable for persuading 45-49 year old male veterans that they should be examined.

How is colon cancer identified?

Your doctor would advise exams and testing to determine the cause if you have colorectal cancer symptoms or if a screening test result was abnormal.

The American College of Physicians advises colorectal cancer screening using one of the following methods for those with a typical risk of developing the disease:

  • a colonoscopy every ten years
  • every two years, a high sensitivity guaiac-based faecal occult blood test (gFOBT) or faecal immunochemical test (FIT)
  • FIT every two years in addition to flexible sigmoidoscopy every ten years.

People who have a higher risk of developing colorectal cancer should discuss the type and frequency of screening that is most appropriate for them with their doctor.

To determine your personal risk level, use this risk calculator. Additional testing is necessary to stage colorectal cancer and determine the best course of therapy if it is discovered.

Physical examination and medical history

To ascertain whether you have any risk factors, such as a family history of colorectal cancer, your doctor will inquire about your medical history. Additionally, the duration of your symptoms will be questioned of you.

During a physical examination, your abdomen will be felt for lumps or enlarged organs, and a digital rectal exam (DRE) may be performed.

A gloved finger is inserted into your rectum by the doctor during a DRE to look for any anomalies.

Stool tests

Tests to look for blood in your stool may be advised by your doctor. To the naked eye, blood in the faeces is not always obvious. These examinations aid in finding blood that cannot be seen.

These tests, such as a FOBT or FIT, are carried out at home with the aid of a kit that is provided. You can use the kit to gather one to three stool samples for testing.

A blood test

Blood tests may be required to look for colorectal cancer symptoms include anaemia, which is a condition when there are not enough red blood cells in the body.

Additionally, your doctor can request tests for liver function and tumour markers such carcinoembryonic antigen (CEA) and CA 19-9. Colorectal cancer cannot be identified by blood testing alone.

Signoidoscopy

Your doctor can view the interior of your sigmoid colon via a sigmoidoscopy, also known as a flexible sigmoidoscopy. If a colonoscopy is not possible for any reason, this less intrusive technique could be suggested instead.

Colonoscopy

A diagnostic colonoscopy is carried out as a result of symptoms you are experiencing or an anomaly discovered during a screening test. The test is performed to observe your colon and rectum in their entirety.

A colonoscope, which is put into the body through the anus, is used to perform it because it is a small, flexible tube with a camera on the end.

The colonoscope can be used to insert specialised tools that can be used to remove polyps and collect tissue samples for biopsies.

Proctoscopy

During a proctoscopy, the anus is used to introduce a proctoscope. To observe the interior of the rectum, a proctoscope is a short, rigid tube with a camera at one end. It is used to examine the rectum for cancer.

Biopsy

A biopsy is a lab test that looks at a tissue sample. Polyps or questionable spots are typically removed during a colonoscopy, but if necessary, they can also be removed surgically.

The tissue is delivered to a lab where a microscope is used to examine it. The samples might also be examined for gene alterations if cancer is discovered. To help categorise the malignancy, more lab tests could be carried out.

Imaging exams

Imaging examinations can:

  • view potential cancerous regions that are suspicious
  • determine the extent of the cancer’s spread
  • test the efficacy of the treatment

REFERENCES:

For Cancer disease medications that have been suggested by doctors worldwide are available here https://mygenericpharmacy.com/index.php?therapy=10

Insulin may boost cognition in cognitive disorder people.

Insulin may boost cognition in cognitive disorder people.

Comments 0 Comment

According to research, certain individuals with dementia-related illnesses may benefit from utilising intranasal insulin.

They claimed that those with Alzheimer’s disease and mild cognitive impairment seem to benefit most from the insulin therapy.

However, other medical professionals claimed that they believed the study to be defective and are not yet prepared to endorse insulin as a treatment for these illnesses.

According to a report published in the journal PLOS ONE, intranasal insulin may have some favourable cognitive effects, especially for those with Alzheimer’s disease and mild cognitive impairment.

Intranasal insulin and cognitive performance were studied in 29 research with 1,726 participants for a review and meta-analysis. The studies’ publications span the years 2001 and 2021.

The average insulin dosage was 40IU. The results of a single dose were investigated in ten trials. The other studies had a median duration of eight weeks and involved multiple doses over a longer period of time. The participants’ average age was around 53.

The subjects were categorised into four categories of disorders by the researchers:

  • illnesses of the mind, including schizophrenia, bipolar disorder, and major depressive disorder
  • Mild cognitive impairment with Alzheimer’s disease
  • metabolic conditions like diabetes
  • Other illnesses

Additionally, a pool of healthy, cognitively unimpaired people was used.

In persons with mental health illnesses, metabolic diseases, and other conditions, the researchers found no discernible difference in cognitive performance following dosages of intranasal insulin, according to their findings.

Participants who had mild cognitive impairment and Alzheimer’s disease showed considerable improvement, according to the researchers.

The potential link between insulin and brain function

According to Dr. Gayatri Devi, a neurologist at Northwell Lenox Hill Hospital in New York who was not involved in the study, “Patients with Alzheimer’s may have impaired glucose processing in the hippocampus (an area of the brain involved in human learning and memory).” Insulin administered intravenously may help with this and enhance cognition.

One explanation for why insulin can help with memory and cognition is that the brain’s memory centres are either defective or unable to handle sugar.

According to Dr. Shae Datta, co-director of NYU Langone’s Concussion Centre and director of cognitive neurology at NYU Langone Hospital-Long Island, “It could be plausible that the amount of insulin receptors in the memory centres in the brain become defective or are simply insufficient to handle sugar.

“Insulin replacement improves brain metabolism. resulting in the hypothesis that brain insulin resistance can cause cognitive problems, according to Datta, a researcher who was not involved in the study.

Intranasal insulin side effects include:

  • Hypoglycemia may cause heart attacks and strokes.
  • Irritation or rhinitis of the nose
  • Lightheadedness
  • Dizziness
  • Nausea
  • a nosebleed

The study’s authors came to the conclusion that intranasal insulin can be safely tolerated and may enhance memory by directly interacting with brain areas involved in the control of cognition.

Response to the study on insulin and cognitive decline

The researchers did say that additional study is required to comprehend therapy response.

Not all medical practitioners find the research to be compelling.

“Overall, I wasn’t impressed with the study,” said Dr. Clifford Segil, DO, a neurologist at Providence Saint John’s Health Centre in California who was not engaged in the study. “Intranasal insulin for diabetes has been tried, but it failed.”

“I find it unsettling to provide insulin to someone who shows no signs of diabetes. Giving insulin to a person who does not have diabetes carries the danger of hypoglycemia, he told us. This could make them more vulnerable to a heart attack or stroke.

Segil continued, “I think that it is good to repurpose medications as it can increase therapy options. But this research does not back up using this medication for memory loss. It was never employed in my practise.

“This is a meta-analysis, so a statistical compilation of multiple studies, most of them quite small,” Devi explained. “This is never as good a big double-blind placebo-controlled study as that would be crucial in patient-related decisions,” the author writes. However, each patient must be handled uniquely, and decisions about the best course of treatment must be made with that patient in mind.

Devi continued, “Intranasal insulin treatment for patients with biomarker-confirmed Alzheimer’s disease still needs a large placebo-controlled study.” Up to a third of individuals who were clinically diagnosed with Alzheimer’s did not have it on pathology, which was a concern in prior Alzheimer’s clinical studies.

REFERENCES:

For Mental disease medications that have been suggested by doctors worldwide are available here https://mygenericpharmacy.com/index.php?cPath=77_478

Increased risk of total mortality linked with loneliness.

Increased risk of total mortality linked with loneliness.

Comments 0 Comment

According to a comprehensive new meta-study, social isolation and loneliness both raise the risk of all-cause mortality.

Additionally, loneliness and social isolation are connected to an increased chance of passing away in cancer patients.

Social isolation, not loneliness, is linked to a higher mortality risk in people with heart disease. A link between social isolation, loneliness, and death has been confirmed by a recent study.

The authors looked into the connections between the two events and deaths from breast cancer, cardiovascular disease, and all other causes.

According to the extensive meta analysis, having a socially isolated lifestyle was linked to a 26% higher chance of dying from any cause than persons who did not have a socially isolated lifestyle.

Although the impact of loneliness was slightly less severe, it was nonetheless alarming: compared to those who were not lonely, those who were lonely for an extended period of time had a 14% increased chance of dying.

An increase in the probability of dying from any cause or from cancer was associated with both social isolation and loneliness. For those with cardiovascular illness, social isolation was likewise linked to an increased chance of passing away.

The meta-study examined the results of 90 distinct research with 2,205,199 participants.

Social isolation vs. loneliness

The study’s finding that social isolation had a bigger impact on mortality than loneliness is one of its more intriguing findings. The two ailments could appear to be similar. But they are not equivalent:

The term “social isolation” is used in the study to describe “an objective lack of (or limited) social contact with other people, and is characterized by a person having a small social network, having infrequent social contacts, or possibly living alone.”

On the other side, “loneliness” is “a subjective feeling of distress, emerging when there is a mismatch between desired and actual social relationships.”

For instance, it is possible to feel lonely in a group of people, even if those people are known, and it is also possible to be socially isolated without experiencing emotions of loneliness.

Effects of social isolation on health

According to Dr. Rosanne Freak-Poli, a senior research fellow in epidemiology at Monash University who was not involved in the study, “two landmark meta-analytical studies have identified that social isolation is a stronger risk factor for mortality than loneliness.”

Without being part in the study, Dr. Angelina R. Sutin, a professor at Florida State University’s College of Medicine, informed us that social isolation can be detrimental for at least a few reasons even when it does not result in loneliness in the individual.

One is that socially isolated person might not have somebody to drive them to the doctor regularly, either because they don’t have transportation or because some procedures call for an assistant.

People are not always aware of changes that are happening to them or when it is time to consult a doctor, Dr. Sutin continued.

Others may be better able to spot changes and obtain the care they require. Dr. Sutin noted that “delaying care can have significant consequences in both cases.”

According to Dr. Freak-Poli’s research, social isolation might lead to some of the harmful reactions linked with loneliness. According to her studies, social isolation and loneliness both have negative consequences on one’s health, including:

  • a high blood pressure level
  • elevated triglycerides
  • obesity and excess weight
  • a lower standard of living
  • unsound mental state

Someone who is socially isolated or lonely is more likely to engage in harmful lifestyle choices, which may exacerbate their situation and make them feel even more alone and alienated, said epidemiologist Dr. Rosanne Freak-Poli.

The impact of technology on social isolation

Our growing reliance on online connections is one reason for social isolation that is frequently brought up in discourse.

For some people, using devices can be socially isolating, while for others it can be a lifeline.

The difficulty now is figuring out when and how online interactions can be good, as well as who will get the most from real-world social interaction as opposed to virtual interaction, she continued.

Dr. Freak-Poli pointed out that the method of internet communication affects whether it is beneficial or harmful.

“Social media can have advantages if it is being used to directly and meaningfully communicate with people,” she said.

According to study, apps like Teams, Zoom, or FaceTime that allow users to see each other’s faces while speaking can increase social interaction, reduce loneliness, and improve overall wellbeing.

Social connections and relationships are beneficial to health

The current meta-study, according to Dr. Sutin, is “a nice summary of that literature and calls attention to the harmful effects of both loneliness and social isolation.”

Additionally, it provides more detailed evidence showing, among particular patient populations, social isolation and loneliness raise the risk of cause-specific mortality. The study emphasises the importance of relationships and social connection as well as the serious implications of not meeting social requirements, according to Dr. Sutin.

Dr. Freak-Poli remarked, “Since they are a part of the human condition, experiencing social isolation and loneliness are regrettably likely inevitable at some point in one’s life.”

Dr. Freak-Poli declared that she thought “initiating social interaction is an achievable goal.”

She claimed to have discovered that engaging in community events at least once a month and keeping in touch with five or more close family members or friends each month can have a significant positive impact on one’s health.

Health effects of severe loneliness

According to Dr. Sutin, loneliness can have a negative impact on health in a number of ways. She noted that lonely people frequently adopt harmful lifestyle habits like:

  • smoking
  • misuse of drugs
  • a rise in sedentary behaviour
  • abandoning activities that stimulate the mind

Dr. Sutin issued a warning that lonely persons “may also be less likely to participate in preventive care and screenings that can both prevent and detect disease at its earliest possible stage, when it is most likely to be treatable.”

We learned about the negative impacts of loneliness on mental health from Dr. Mary Louise Pomeroy, Ph.D., MPH, a postdoctoral research fellow at Johns Hopkins University:

“Loneliness is of particular concern for poor mental health (depression, stress, anxiety), which may lead to a higher risk of mortality through negative health behaviors, either directly (i.e., suicide) or indirectly (e.g., smoking as a social activity or to alleviate boredom or distress).”

Of course, being alone is unpleasant, and persistent stress has been related to a number of health problems.

Although the study’s authors concluded that social isolation posed a higher risk to health than loneliness did, they did not downplay the negative effects of chronic loneliness, which can have an impact on anyone.

Extreme versus infrequent loneliness

Dr. Freak-Poli made the observation that the study is focused on extreme loneliness. “For instance, from a health perspective, feeling lonely one day a week, even if it is regular, is not all that concerning.”

However, Dr. Freak-Poli said, “There is evidence that it is likely to have an impact on their health and well-being if they experience lonely three or more days a week over time. Other studies have shown that the COVID-19 pandemic was associated with an increase in loneliness.”

The majority, if not all, COVID-related social constraints, however, no longer apply depending on where you live. She also mentioned that, in contrast to pre-pandemic days, we are now more aware of how we communicate and socialise.

For instance, after getting perspective from their previously overly busy lives, some people may prefer to socialise less.

In spite of this, the U.S. Surgeon General has issued a warning about a “loneliness epidemic” and a recommendation on the value of social connection. According to Dr. Freak-Poli, she is not shocked.

“COVID-19 altered the way we live our daily lives and increased our awareness of interpersonal interactions. It is now impossible to ignore this awareness of human social interaction, she remarked.

Dr. Freak-Poli came to the conclusion that community services and programmes are gradually being reestablished, and that this may enable people who have recently experienced loneliness make social ties.

REFERENCES:

For Mental disease medications that have been suggested by doctors worldwide are available here https://mygenericpharmacy.com/index.php?cPath=77_478